MARATTO

article · BMJ Open

Psychometric properties of the Generalised Anxiety Disorder-7 (GAD-7) screening tool in people living with HIV: the Afaan Oromoo version

2026Open accessJimma University

Abstract

OBJECTIVE: The aim of the study was to assess the psychometric properties of the Afaan Oromoo version of Generalised Anxiety Disorder-7 (GAD-7) scale among people living with HIV. DESIGN: A hospital-based cross-sectional study. SETTING: The study was conducted at a tertiary-level antiretroviral therapy clinic. PARTICIPANTS: The study included 163 people living with HIV. PRIMARY OUTCOME MEASURES: The GAD-7 scale was evaluated against the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition diagnostic criteria for GAD as the gold standard. RESULT: A total of 163 participants were enrolled (response rate: 98.2%). The Afaan Oromoo GAD-7 demonstrated excellent internal consistency (Cronbach's alpha=0.92). A cut-off score of ≥9 provided the optimal balance between sensitivity (89.19%) and specificity (85.75%), with an area under curve of 0.91, a positive predictive value of 64.7% and negative predictive value of 96.4%. Confirmatory factor analysis supported a one-factor structure. CONCLUSIONS: The findings indicate that the Afaan Oromoo version of the GAD-7 is a valid and reliable tool for screening GAD among adults receiving HIV care. Routine use of the GAD-7 in antiretroviral therapy clinics is recommended to support early identification of anxiety symptoms.

Research topics

  • Bipolar Disorder and Treatment
  • HIV/AIDS Research and Interventions
  • Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes

Sustainable Development Goals

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.1136/bmjopen-2025-106016

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.